Angiogenesis inhibition for the improvement of photodynamic therapy: The revival of a promising idea

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 1, 2012, Pages 53-70

  Weiss, Andrea ^a   Den Bergh, Hubert van ^a   Griffioen, Arjan W ^b   Nowak Sliwinska, Patrycja ^b,c  

^a EPFL   (Switzerland)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiogenesis inhibitors; Endothelial cells; Photodynamic therapy; Photosensitizer; Targeting; Vascular normalization

Indexed keywords

AMINOLEVULINIC ACID; BEVACIZUMAB; CELECOXIB; CETUXIMAB; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOOXYGENASE 2; ERLOTINIB; FIBRONECTIN; FUMAGILLOL CHLOROACETYLCARBAMATE; HYPERICIN; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY DC101; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ORANTINIB; PHOTOFRIN; PRINOMASTAT; ROFECOXIB; SEMAXANIB; SORAFENIB; SUNITINIB; VADIMEZAN; VASCULOTROPIN; VERTEPORFIN; VITRONECTIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; BLADDER CANCER; BLADDER CARCINOMA; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CAPILLARY HEMANGIOMA; CHOROID TUMOR; COLON ADENOCARCINOMA; COLON CANCER; COLON CARCINOMA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; FIBROSARCOMA; GLIOBLASTOMA; HEMANGIOMA; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; MONOTHERAPY; NASOPHARYNX CARCINOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 84859498670     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.03.003     Document Type: Review

References (182)

1. Ghaliounghui P. The Ebers Papyrus: A New English Translation, Commentaries and Glossaries 1987, Egyptian Academy of Scientific Research and Technology, Cairo.
2. Raab O. Ueber die Wirkung Fluorescierenden Stoffe auf Infusorien. Z. Biol. 1904, 39:524-546.
3. Jesionek H., von Tappeiner H. Zur Behandlung der Hautcarcinome mit fluoreszierenden Stoffen. Dtsch. Arch. Klin. Med 1905, 82:223-226.
4. Dougherty T.J., Kaufman J.E., Goldfarb A., Weishaupt K.R., Boyle D., Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978, 38:2628-2635.
5. Van den Bergh H.B., J.-P. Photodynamic therapy: basic principles and mechanisms. Lasers Opthalmol. 2003, 183-195.
6. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., Moan J., Peng Q. Photodynamic therapy. J. Natl. Cancer Inst. 1998, 90:889-905.
7. Nowak-Sliwinska P., Karocki A., Elas M., Pawlak A., Stochel G., Urbanska K. Verteporfin, photofrin II, and merocyanine 540 as PDT photosensitizers against melanoma cells. Biochem. Biophys. Res. Commun. 2006, 349:549-555.
8. Chen B., Pogue B.W., Luna J.M., Hardman R.L., Hoopes P.J., Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin. Cancer Res. 2006, 12:917-923.
9. Korbelik M. PDT-associated host response and its role in the therapy outcome. Lasers Surg. Med. 2006, 38:500-508.
10. Fantini F., Greco A., Del Giovane C., Cesinaro A.M., Venturini M., Zane C., Surrenti T., Peris K., Calzavara-Pinton P.G. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J. Eur. Acad. Dermatol. Venereol. 2011, 25:896-901.
11. Biel M.A. Photodynamic therapy treatment of early oral and laryngeal cancers. Photochem. Photobiol. 2007, 83:1063-1068.
12. Rigual N.R., Thankappan K., Cooper M., Sullivan M.A., Dougherty T., Popat S.R., Loree T.R., Biel M.A., Henderson B. Photodynamic therapy for head and neck dysplasia and cancer. Arch. Otolaryngol. Head Neck Surg. 2009, 135:784-788.
13. Klein A., Babilas P., Karrer S., Landthaler M., Szeimies R.M. Photodynamic therapy in dermatology-an update 2008. J. Dtsch. Dermatol. Ges. 2008, 6:839-845. 839-846.
14. Moghissi K., Dixon K., Thorpe J.A., Stringer M., Oxtoby C. Photodynamic therapy (PDT) in early central lung cancer: a treatment option for patients ineligible for surgical resection. Thorax 2007, 62:391-395.
15. Usuda J., Kato H., Okunaka T., Furukawa K., Tsutsui H., Yamada K., Suga Y., Honda H., Nagatsuka Y., Ohira T., Tsuboi M., Hirano T. Photodynamic therapy (PDT) for lung cancers. J. Thorac. Oncol. 2006, 1:489-493.
16. Sun J., Cecic I., Parkins C.S., Korbelik M. Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours. Photochem. Photobiol. Sci. 2002, 1:690-695.
17. Gollnick S.O., Evans S.S., Baumann H., Owczarczak B., Maier P., Vaughan L., Wang W.C., Unger E., Henderson B.W. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br. J. Cancer 2003, 88:1772-1779.
18. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D., Korbelik M., Moan J., Mroz P., Nowis D., Piette J., Wilson B.C., Golab J. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 2011, 61:250-281.
19. van Geel I.P., Oppelaar H., Rijken P.F., Bernsen H.J., Hagemeier N.E., van der Kogel A.J., Hodgkiss R.J., Stewart F.A. Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy. Br. J. Cancer 1996, 73:288-293.
20. Henderson B.W., Dougherty T.J. How does photodynamic therapy work?. Photochem. Photobiol. 1992, 55:145-157.
21. Hopper C. Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol. 2000, 1:212-219.
22. Nowak-Sliwinska P., Wagnieres G., van den Bergh H., Griffioen A.W. Angiostasis-induced vascular normalization can improve photodynamic therapy. Cell. Mol. Life Sci. 2010, 67:1559-1560.
23. P. Nowak-Sliwinska, A. Weiss, J.R. Beijnum, T.J. Wong, J.P. Ballini, B. Lovisa, H.V. Bergh, A.W. Griffioen, Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion, J. Cell. Mol. Med., in press, PMID: 21880113.
24. Moor A.C. Signaling pathways in cell death and survival after photodynamic therapy. J. Photochem. Photobiol. B 2000, 57:1-13.
25. Ferrario A., von Tiehl K.F., Rucker N., Schwarz M.A., Gill P.S., Gomer C.J. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000, 60:4066-4069.
26. Nahabedian M.Y., Cohen R.A., Contino M.F., Terem T.M., Wright W.H., Berns M.W., Wile A.G. Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors. J. Natl. Cancer Inst. 1988, 80:739-743.
27. Golab J., Olszewska D., Mroz P., Kozar K., Kaminski R., Jalili A., Jakobisiak M. Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia. Clin. Cancer Res. 2002, 8:1265-1270.
28. Luksiene Z., Kalvelyte A., Supino R. On the combination of photodynamic therapy with ionizing radiation. J. Photochem. Photobiol. B 1999, 52:35-42.
29. Bhuvaneswari R., Gan Y.Y., Soo K.C., Olivo M. The effect of photodynamic therapy on tumor angiogenesis. Cell. Mol. Life Sci. 2009, 66:2275-2283.
30. Fingar V.H., Kik P.K., Haydon P.S., Cerrito P.B., Tseng M., Abang E., Wieman T.J. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br. J. Cancer 1999, 79:1702-1708.
31. Henderson B.W., Waldow S.M., Mang T.S., Potter W.R., Malone P.B., Dougherty T.J. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res. 1985, 45:572-576.
32. Nowak-Sliwinska P., van Beijnum J.R., van Berkel M., van den Bergh H., Griffioen A.W. Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis 2010, 13:281-292.
33. Star W.M., Marijnissen H.P., van den Berg-Blok A.E., Versteeg J.A., Franken K.A., Reinhold H.S. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res. 1986, 46:2532-2540.
34. van den Bergh H., Ballini J.P. Photodynamic therapy: basic principle. Lasers in Ophthalmology-Basic, diagnostic and Surgical Aspects 2003, 183-195. Kugler Publications, The Hague. S. F.F.a.K. (Ed.).
35. Foster T.H., Primavera M.C., Marder V.J., Hilf R., Sporn L.A. Photosensitized release of von Willebrand factor from cultured human endothelial cells. Cancer Res. 1991, 51:3261-3266.
36. Nelson J.S., Liaw L.H., Berns M.W. Tumor destruction in photodynamic therapy. Photochem. Photobiol. 1987, 46:829-835.
37. Schmidt-Erfurth U., Hasan T., Gragoudas E., Michaud N., Flotte T.J., Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994, 101:1953-1961.
38. Solomon H.M., Zieve P.D., Krevans J.R. The effect of hematoporphyrin and light on human platelets. II. Uptake of hematoporphyrin. J. Cell. Physiol. 1966, 67:281-284.
39. Zieve P.D., Solomon H.M., Krevans J.R. The effect of hematoporphyrin and light on human platelets. I. Morphologic, functional, and biochemical changes. J. Cell. Physiol. 1966, 67:271-279.
40. Henderson B.W., Owczarczak B., Sweeney J., Gessner T. Effects of photodynamic treatment of platelets or endothelial cells in vitro on platelet aggregation. Photochem. Photobiol. 1992, 56:513-521.
41. Reed M.W., Miller F.N., Wieman T.J., Tseng M.T., Pietsch C.G. The effect of photodynamic therapy on the microcirculation. J. Surg. Res. 1988, 45:452-459.
42. Fingar V.H. Vascular effects of photodynamic therapy. J. Clin. Laser Med. Surg. 1996, 14:323-328.
43. Klausner J.M., Paterson I.S., Goldman G., Kobzik L., Rodzen C., Lawrence R., Valeri C.R., Shepro D., Hechtman H.B. Postischemic renal injury is mediated by neutrophils and leukotrienes. Am. J. Physiol. 1989, 256:F794-F802.
44. Doukas J., Hechtman H.B., Shepro D. Vasoactive amines and eicosanoids interactively regulate both polymorphonuclear leukocyte diapedesis and albumin permeability in vitro. Microvasc. Res. 1989, 37:125-137.
45. Fingar V.H., Wieman T.J., Wiehle S.A., Cerrito P.B. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res. 1992, 52:4914-4921.
46. Dellian M., Abels C., Kuhnle G.E., Goetz A.E. Effects of photodynamic therapy on leucocyte-endothelium interaction: differences between normal and tumour tissue. Br. J. Cancer 1995, 72:1125-1130.
47. Griffioen A.W., Damen C.A., Martinotti S., Blijham G.H., Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 1996, 56:1111-1117.
48. Dirkx A.E., Oude Egbrink M.G., Kuijpers M.J., van der Niet S.T., Heijnen V.V., Bouma-ter Steege J.C., Wagstaff J., Griffioen A.W. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003, 63:2322-2329.
49. Ben-Hur E., Heldman E., Crane S.W., Rosenthal I. Release of clotting factors from photosensitized endothelial cells: a possible trigger for blood vessel occlusion by photodynamic therapy. FEBS Lett. 1988, 236:105-108.
50. Chang W.H., Petry J.J. Platelets, prostaglandins, and patency in microvascular surgery. J. Microsurg. 1980, 2:27-35.
51. Ogletree M.L. Overview of physiological and pathophysiological effects of thromboxane A2. Fed. Proc. 1987, 46:133-138.
52. Gilissen M.J., van de Merbel-de Wit L.E., Star W.M., Koster J.F., Sluiter W. Effect of photodynamic therapy on the endothelium-dependent relaxation of isolated rat aortas. Cancer Res. 1993, 53:2548-2552.
53. Fingar V.H., Wieman T.J., Doak K.W. Changes in tumor interstitial pressure induced by photodynamic therapy. Photochem. Photobiol. 1991, 53:763-768.
54. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (New York, N.Y.) 2005, 307:58-62.
55. Cao D., Hou M., Guan Y.S., Jiang M., Yang Y., Gou H.F. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer 2009, 9:432.
56. Fernando N.H., Hurwitz H.I. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 2004, 9(Suppl. 1):11-18.
57. Couch S.M., Bakri S.J. Review of combination therapies for neovascular age-related macular degeneration. Semin. Ophthalmol. 2011, 26:114-120.
58. R.Y.Bhuvaneswari G.Y., Chee S.K., Olivo M. Antiangiogenesis agents Avastin and Erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model. Lasers Surg. Med. 2011, 43:651-662.
59. Ferrario A., Gomer C.J. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J. Environ. Pathol. Toxicol. Oncol. 2006, 25:251-259.
60. Bhuvaneswari R., Yuen G.Y., Chee S.K., Olivo M. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. Photochem. Photobiol. Sci. 2007, 6:1275-1283.
61. Bhuvaneswari R., Thong P.S., Gan Y.Y., Soo K.C., Olivo M. Evaluation of hypericin-mediated photodynamic therapy in combination with angiogenesis inhibitor bevacizumab using in vivo fluorescence confocal endomicroscopy. J. Biomed. Opt. 2010, 15:011114.
62. Jiang F., Zhang X., Kalkanis S.N., Zhang Z., Yang H., Katakowski M., Hong X., Zheng X., Zhu Z., Chopp M. Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma. Photochem. Photobiol. 2008, 84:128-137.
63. Sagong M., Lee J., Chang W. Application of intravitreal bevacizumab for circumscribed choroidal hemangioma. Korean J. Ophthalmol. 2009, 23:127-131.
64. Verbraak F.D., Schlingemann R.O., de Smet M.D., Keunen J.E. Single spot PDT in patients with circumscribed choroidal haemangioma and near normal visual acuity. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 244:1178-1182.
65. Baba T., Kitahashi M., Kubota-Taniai M., Oshitari T., Yamamoto S. Subretinal hemorrhage after photodynamic therapy for juxtapapillary retinal capillary hemangioma. Case Rep. Ophthalmol. 2011, 2:134-139.
66. Ziemssen F., Voelker M., Inhoffen W., Bartz-Schmidt K.U., Gelisken F. Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye (Lond.) 2007, 21:1125-1126.
67. Kim K.J., Li B., Houck K., Winer J., Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992, 7:53-64.
68. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
69. Gerber H.P., Wu X., Yu L., Wiesmann C., Liang X.H., Lee C.V., Fuh G., Olsson C., Damico L., Xie D., Meng Y.G., Gutierrez J., Corpuz R., Li B., Hall L., Rangell L., Ferrando R., Lowman H., Peale F., Ferrara N. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3478-3483.
70. Bock F., Onderka J., Dietrich T., Bachmann B., Kruse F.E., Paschke M., Zahn G., Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Investig. Ophthalmol. Vis. Sci. 2007, 48:2545-2552.
71. Yu L., Wu X., Cheng Z., Lee C.V., LeCouter J., Campa C., Fuh G., Lowman H., Ferrara N. Interaction between bevacizumab and murine VEGF-A: a reassessment. Investig. Ophthalmol. Vis. Sci. 2008, 49:522-527.
72. Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94:1593-1611.
73. del Carmen M.G., Rizvi I., Chang Y., Moor A.C., Oliva E., Sherwood M., Pogue B., Hasan T. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J. Natl. Cancer Inst. 2005, 97:1516-1524.
74. Kim E.S., Khuri F.R., Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Curr. Opin. Oncol. 2001, 13:506-513.
75. Martinez-Carpio P.A., Trelles M.A. The role of epidermal growth factor receptor in photodynamic therapy: a review of the literature and proposal for future investigation. Lasers Med. Sci. 2010, 25:767-771.
76. Bhuvaneswari R., Gan Y.Y., Soo K.C., Olivo M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol. Cancer 2009, 8:94.
77. Yip W.L., Weyergang A., Berg K., Tonnesen H.H., Selbo P.K. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol. Pharm. 2007, 4:241-251.
78. Berg K., Selbo P.K., Prasmickaite L., Tjelle T.E., Sandvig K., Moan J., Gaudernack G., Fodstad O., Kjolsrud S., Anholt H., Rodal G.H., Rodal S.K., Hogset A. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 1999, 59:1180-1183.
79. Lustig R.A., Vogl T.J., Fromm D., Cuenca R., Alex Hsi R., D'Cruz A.K., Krajina Z., Turic M., Singhal A., Chen J.C. A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer 2003, 98:1767-1771.
80. Manyak M.J., Ogan K. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. J. Endourol. 2003, 17:633-639.
81. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat. Rev. Cancer 2005, 5:735-743.
82. Herbst R.S., Johnson D.H., Mininberg E., Carbone D.P., Henderson T., Kim E.S., Blumenschein G., Lee J.J., Liu D.D., Truong M.T., Hong W.K., Tran H., Tsao A., Xie D., Ramies D.A., Mass R., Seshagiri S., Eberhard D.A., Kelley S.K., Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005, 23:2544-2555.
83. Iyer R., Fetterly G., Lugade A., Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert. Opin. Pharmacother. 2010, 11:1943-1955.
84. Van den Eynde M., Baurain J.F., Mazzeo F., Machiels J.P. Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin. Belg. 2011, 66:10-17.
85. Powles T., Chowdhury S., Jones R., Mantle M., Nathan P., Bex A., Lim L., Hutson T. Sunitinib and other targeted therapies for renal cell carcinoma. Br. J. Cancer 2011, 104:741-745.
86. Dimitroff C.J., Klohs W., Sharma A., Pera P., Driscoll D., Veith J., Steinkampf R., Schroeder M., Klutchko S., Sumlin A., Henderson B., Dougherty T.J., Bernacki R.J. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest. New Drugs 1999, 17:121-135.
87. Zhou Q., Olivo M., Lye K.Y., Moore S., Sharma A., Chowbay B. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother. Pharmacol. 2005, 56:569-577.
88. Mendel D.B., Schreck R.E., West D.C., Li G., Strawn L.M., Tanciongco S.S., Vasile S., Shawver L.K., Cherrington J.M. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res. 2000, 6:4848-4858.
89. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 1999, 189:300-308.
90. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 1999, 103:1237-1241.
91. Du H., Olivo M., Mahendran R., Bay B.H. Modulation of Matrix metalloproteinase-1 in nasopharyngeal cancer cells by photoactivation of hypericin. Int. J. Oncol. 2004, 24:657-662.
92. Du H.Y., Olivo M., Mahendran R., Huang Q., Shen H.M., Ong C.N., Bay B.H. Hypericin photoactivation triggers down-regulation of matrix metalloproteinase-9 expression in well-differentiated human nasopharyngeal cancer cells. Cell. Mol. Life Sci. 2007, 64:979-988.
93. Tabruyn S.P., Memet S., Ave P., Verhaeghe C., Mayo K.H., Struman I., Martial J.A., Griffioen A.W. NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Mol. Cancer Ther. 2009, 8:2645-2654.
94. Tabruyn S.P., Griffioen A.W. NF-kappa B: a new player in angiostatic therapy. Angiogenesis 2008, 11:101-106.
95. Au C.M., Luk S.K., Jackson C.J., Ng H.K., Yow C.M., To S.S. Differential effects of photofrin, 5-aminolevulinic acid and calphostin C on glioma cells. J. Photochem. Photobiol. B 2006, 85:92-101.
96. Sharwani A., Jerjes W., Hopper C., Lewis M.P., El-Maaytah M., Khalil H.S., Macrobert A.J., Upile T., Salih V. Photodynamic therapy down-regulates the invasion promoting factors in human oral cancer. Arch. Oral Biol. 2006, 51:1104-1111.
97. Chu E.S., Wong T.K., Yow C.M. Photodynamic effect in medulloblastoma: downregulation of matrix metalloproteinases and human telomerase reverse transcriptase expressions. Photochem. Photobiol. Sci. 2008, 7:76-83.
98. Ferrario A., Chantrain C.F., von Tiehl K., Buckley S., Rucker N., Shalinsky D.R., Shimada H., DeClerck Y.A., Gomer C.J. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res. 2004, 64:2328-2332.
99. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000, 19:19-27.
100. Gately S., Li W.W. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol. 2004, 31:2-11.
101. Wang M.T., Honn K.V., Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 2007, 26:525-534.
102. Romano M., Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. 2003, 17:1986-1995.
103. Kinoshita T., Takahashi Y., Sakashita T., Inoue H., Tanabe T., Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim. Biophys. Acta 1999, 1438:120-130.
104. Singh B., Berry J.A., Shoher A., Ramakrishnan V., Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int. J. Oncol. 2005, 26:1393-1399.
105. Petkova D.K., Clelland C., Ronan J., Pang L., Coulson J.M., Lewis S., Knox A.J. Overexpression of cyclooxygenase-2 in non-small cell lung cancer. Respir. Med. 2004, 98:164-172.
106. Cao Y., Prescott S.M. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell. Physiol. 2002, 190:279-286.
107. Ferrario A., Von Tiehl K., Wong S., Luna M., Gomer C.J. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 2002, 62:3956-3961.
108. Harvey E.H., Webber J., Kessel D., Fromm D. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398. Am. J. Surg. 2005, 189:302-305.
109. Makowski M., Grzela T., Niderla J., L.A.M., Mroz P., Kopee M., Legat M., Strusinska K., Koziak K., Nowis D., Mrowka P., Wasik M., Jakobisiak M., Golab J. Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin. Cancer Res. 2003, 9:5417-5422.
110. Ferrario A., Fisher A.M., Rucker N., Gomer C.J. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res. 2005, 65:9473-9478.
111. Yee K.K., Soo K.C., Olivo M. Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. Int. J. Mol. Med. 2005, 16:993-1002.
112. Akita Y., Kozaki K., Nakagawa A., Saito T., Ito S., Tamada Y., Fujiwara S., Nishikawa N., Uchida K., Yoshikawa K., Noguchi T., Miyaishi O., Shimozato K., Saga S., Matsumoto Y. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Br. J. Dermatol. 2004, 151:472-480.
113. Hendrickx N., Dewaele M., Buytaert E., Marsboom G., Janssens S., Van Boven M., Vandenheede J.R., de Witte P., Agostinis P. Targeted inhibition of p38alpha MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy. Biochem. Biophys. Res. Commun. 2005, 337:928-935.
114. Hendrickx N., Volanti C., Moens U., Seternes O.M., de Witte P., Vandenheede J.R., Piette J., Agostinis P. Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J. Biol. Chem. 2003, 278:52231-52239.
115. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348:555-557.
116. Hama Y., Shimizu T., Hosaka S., Sugenoya A., Usuda N. Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. Exp. Toxicol. Pathol. 1997, 49:239-247.
117. Yeh J.R., Mohan R., Crews C.M. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12782-12787.
118. Solban N., Selbo P.K., Sinha A.K., Chang S.K., Hasan T. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res. 2006, 66:5633-5640.
119. Kosharskyy B., Solban N., Chang S.K., Rizvi I., Chang Y., Hasan T. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res. 2006, 66:10953-10958.
120. Kieran M.W., Turner C.D., Rubin J.B., Chi S.N., Zimmerman M.A., Chordas C., Klement G., Laforme A., Gordon A., Thomas A., Neuberg D., Browder T., Folkman J. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J. Pediatr. Hematol. Oncol. 2005, 27:573-581.
121. Lim S.H., Nowak-Sliwinska P., Kamarulzaman F.A., van den Bergh H., Wagnieres G., Lee H.B. The neovessel occlusion efficacy of 15-hydroxypurpurin-7-lactone dimethyl ester induced with photodynamic therapy. Photochem. Photobiol. 2010, 86:397-402.
122. Lim S.H., Thivierge C., Nowak-Sliwinska P., Han J., van den Bergh H., Wagnieres G., Burgess K., Lee H.B. In vitro and in vivo photocytotoxicity of boron dipyrromethene derivatives for photodynamic therapy. J. Med. Chem. 2010, 53:2865-2874.
123. Nowak-Sliwinska P., van Beijnum J.R., Casini A., Nazarov A.A., Wagnieres G., van den Bergh H., Dyson P.J., Griffioen A.W. Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J. Med. Chem. 2011, 54:3895-3902.
124. Zuluaga M.F., Lange N. Combination of photodynamic therapy with anti-cancer agents. Curr. Med. Chem. 2008, 15:1655-1673.
125. Dings R.P., Loren M., Heun H., McNiel E., Griffioen A.W., Mayo K.H., Griffin R.J. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 2007, 13:3395-3402.
126. Murata R., Nishimura Y., Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1997, 37:1107-1113.
127. Ma J., Mai H.Q., Hong M.H., Min H.Q., Mao Z.D., Cui N.J., Lu T.X., Mo H.Y. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J. Clin. Oncol. 2001, 19:1350-1357.
128. Kakeji Y., Teicher B.A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest. New Drugs 1997, 15:39-48.
129. Baguley B.C. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 2003, 4:141-148.
130. Galbraith S.M., Maxwell R.J., Lodge M.A., Tozer G.M., Wilson J., Taylor N.J., Stirling J.J., Sena L., Padhani A.R., Rustin G.J. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 2003, 21:2831-2842.
131. McKeage M.J., Baguley B.C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010, 116:1859-1871.
132. Lambin P., Landuyt W. Vascular targeting: a potential additional anti-cancer treatment. Verh. K. Acad. Geneeskd. Belg. 2003, 65:29-46.
133. Siemann D.W., Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer. Res. 2008, 28:2027-2031.
134. Siim B.G., Lee A.E., Shalal-Zwain S., Pruijn F.B., McKeage M.J., Wilson W.R. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother. Pharmacol. 2003, 51:43-52.
135. Lara P.N., Douillard J.Y., Nakagawa K., von Pawel J., McKeage M.J., Albert I., Losonczy G., Reck M., Heo D.S., Fan X., Fandi A., Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:2965-2971.
136. Murata R., Siemann D.W., Overgaard J., Horsman M.R. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat. Res. 2001, 156:503-509.
137. Seshadri M., Bellnier D.A. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. Photochem. Photobiol. 2009, 85:50-56.
138. He C., Fateya B., Chen B. Combination of vascular targeting PDT with combretastatin A4 phosphate. Proc. SPIE 2009, 7380:7380321-7380326.
139. Fateye B., Chen B. combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells. Proc. SPIE 2009, 7886. 78860B78861-78816.
140. Marrero A., Becker T., Sunar U., Morgan J., Bellnier D. Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses. Photochem. Photobiol. 2011, 87:910-919.
141. Ahmed B., Van Eijk L.I., Bouma-Ter Steege J.C., Van Der Schaft D.W., Van Esch A.M., Joosten-Achjanie S.R., Lambin P., Landuyt W., Griffioen A.W. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int. J. Cancer 2003, 105:20-25.
142. van Beijnum J.R., Dings R.P., van der Linden E., Zwaans B.M., Ramaekers F.C., Mayo K.H., Griffioen A.W. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006, 108:2339-2348.
143. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science (New York, N.Y.) 2000, 289:1197-1202.
144. Folli S., Westermann P., Braichotte D., Pelegrin A., Wagnieres G., van den Bergh H., Mach J.P. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res. 1994, 54:2643-2649.
145. Yarmush M.L., Thorpe W.P., Strong L., Rakestraw S.L., Toner M., Tompkins R.G. Antibody Targeted Photolysis. Crit. Rev. Ther. Drug Carrier Syst. 1993, 10:197-252.
146. Santimaria M., Moscatelli G., Viale G.L., Giovannoni L., Neri G., Viti F., Leprini A., Borsi L., Castellani P., Zardi L., Neri D., Riva P. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 2003, 9:571-579.
147. Birchler M., Viti F., Zardi L., Spiess B., Neri D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat. Biotechnol. 1999, 17:984-988.
148. Palumbo A., Hauler F., Dziunycz P., Schwager K., Soltermann A., Pretto F., Alonso C., Hofbauer G.F., Boyle R.W., Neri D. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br. J. Cancer 2011, 104:1106-1115.
149. Fabbrini M., Trachsel E., Soldani P., Bindi S., Alessi P., Bracci L., Kosmehl H., Zardi L., Neri D., Neri P. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int. J. Cancer 2006, 118:1805-1813.
150. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52:237-268.
151. Cheresh D.A. Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. Cancer Metastasis Rev. 1991, 10:3-10.
152. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (New York, N.Y.) 1994, 264:569-571.
153. Garanger E., Boturyn D., Dumy P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med. Chem. 2007, 7:552-558.
154. Chen J.X., Wang H.Y., Li C., Han K., Zhang X.Z., Zhuo R.X. Construction of surfactant-like tetra-tail amphiphilic peptide with RGD ligand for encapsulation of porphyrin for photodynamic therapy. Biomaterials 2011, 32:1678-1684.
155. Goldman M.J., Wilson J.M. Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J. Virol. 1995, 69:5951-5958.
156. Allen C.M., Sharman W.M., La Madeleine C., Weber J.M., Langlois R., Ouellet R., van Lier J.E. Photodynamic therapy: tumor targeting with adenoviral proteins. Photochem. Photobiol. 1999, 70:512-523.
157. Asai T., Shimizu K., Kondo M., Kuromi K., Watanabe K., Ogino K., Taki T., Shuto S., Matsuda A., Oku N. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett. 2002, 520:167-170.
158. Ichikawa K., Hikita T., Maeda N., Yonezawa S., Takeuchi Y., Asai T., Namba Y., Oku N. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim. Biophys. Acta 2005, 1669:69-74.
159. Oku N., Ishii T. Antiangiogenic photodynamic therapy with targeted liposomes. Methods Enzymol. 2009, 465:313-330.
160. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2002, 2:727-739.
161. Frese K.K., Tuveson D.A. Maximizing mouse cancer models. Nat. Rev. Cancer 2007, 7:645-658.
162. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J.S., Horsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D.R., Blanckmeister C., Chao R., Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011, 364:501-513.
163. Yao J.C., Shah M.H., Ito T., Bohas C.L., Wolin E.M., Van Cutsem E., Hobday T.J., Okusaka T., Capdevila J., de Vries E.G., Tomassetti P., Pavel M.E., Hoosen S., Haas T., Lincy J., Lebwohl D., Oberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011, 364:514-523.
164. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
165. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315:115-122.
166. Tuveson D., Hanahan D. Translational medicine: cancer lessons from mice to humans. Nature 2011, 471:316-317.
167. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
168. Gotink K.J., Broxterman H.J., Labots M., de Haas R.R., Dekker H., Honeywell R.J., Rudek M.A., Beerepoot L.V., Musters R.J., Jansen G., Griffioen A.W., Assaraf Y.G., Pili R., Peters G.J., Verheul H.M. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 2011, 17:7337-7346.
169. A.W. Griffioen, L. Mans, A.M. de Graaf, P. Nowak-Sliwinska, S. Bosch, C. de Hoog, T. Dellemijn, F. Vyth-Dreese, A. Bex, E. Jonasch, Preoperative sunitinib treatment of RCC patients inhibits angiogenesis in the primary tumor; rapid angiogenesis onset after discontinuation of treatment, Clin. Cancer Res., in press.
170. Kabingu E., Vaughan L., Owczarczak B., Ramsey K.D., Gollnick S.O. CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br. J. Cancer 2007, 96:1839-1848.
171. Thong P.S., Ong K.W., Goh N.S., Kho K.W., Manivasager V., Bhuvaneswari R., Olivo M., Soo K.C. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol. 2007, 8:950-952.
172. Thong P.S., Olivo M., Kho K.W., Bhuvaneswari R., Chin W.W., Ong K.W., Soo K.C. Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy. J. Environ. Pathol. Toxicol. Oncol. 2008, 27:35-42.
173. Gollnick S.O., Brackett C.M. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol. Res. 2010, 46:216-226.
174. Castano A.P., Mroz P., Hamblin M.R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer 2006, 6:535-545.
175. Kabingu E., Oseroff A.R., Wilding G.E., Gollnick S.O. Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin. Cancer Res. 2009, 15:4460-4466.
176. Li F., Cheng Y., Lu J., Hu R., Wan Q., Feng H. Photodynamic therapy boosts anti-glioma immunity in mice: a dependence on the activities of T cells and complement C3. J. Cell. Biochem. 2011, 112:3035-3043.
177. Framme C., Sachs H.G., Flucke B., Theisen-Kunde D., Birngruber R. Evaluation of the new photosensitizer Tookad (WST09) for photodynamic vessel occlusion of the choroidal tissue in rabbits. Invest. Ophthalmol. Vis. Sci. 2006, 47:5437-5446.
178. Moore C.M., Mosse C.A., Allen C., Payne H., Emberton M., Bown S.G. Light penetration in the human prostate: a whole prostate clinical study at 763 nm. J. Biomed. Opt. 2011, 16:015003.
179. J.R. van Beijnum, P. Nowak-Sliwinska, E. van den Boezem, P. Hautvast, W. Buurman, A. Griffioen, Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1, Oncogene, in press, PMID:22391561.
180. Kluza E., van der Schaft D.W., Hautvast P.A., Mulder W.J., Mayo K.H., Griffioen A.W., Strijkers G.J., Nicolay K. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 2010, 10:52-58.
181. Thijssen V.L., Postel R., Brandwijk R.J., Dings R.P., Nesmelova I., Satijn S., Verhofstad N., Nakabeppu Y., Baum L.G., Bakkers J., Mayo K.H., Poirier F., Griffioen A.W. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15975-15980.
182. Griffioen A.W., van der Schaft D.W., Barendsz-Janson A.F., Cox A., Struijker Boudier H.A., Hillen H.F., Mayo K.H. Anginex, a designed peptide that inhibits angiogenesis. Biochem. J. 2001, 354:233-242.